{"filing":{"accession_number":"0001193125-26-345702","cik":"0001830487","ticker":"PHVS","company_name":"Pharvaris N.V.","form":"6-K","filing_date":"2026-08-12","report_date":"2026-06-30","primary_document":"phvs-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-20260630.htm"},"events":[{"id":27005,"run_id":24572,"accession_number":"0001193125-26-345702","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release announcing Pharvaris' second quarter 2026 financial results, including Q2 2026 cash position (€318 million), R\u0026D expenses (€35.0 million), G\u0026A expenses (€15.8 million), and net loss (€47.8 million or €0.70 per share). The document explicitly states \"announced financial results for the second quarter ending on June 30, 2026\" and includes a \"Second Quarter 2026 Financial Results\" section with key financial metrics. While the release also contains business updates on clinical trials and a corporate promotion, the primary disclosure is the quarterly financial results, which is material to investors assessing the company's financial position and burn rate.","company_name":"Pharvaris N.V.","ticker":"PHVS","filing_date":"2026-08-12","form":"6-K","submitted_at":null,"items":[{"id":28334,"accession_number":"0001193125-26-345702","item_number":"EX-99.1","item_title":"phvs-ex99_1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing Pharvaris' second quarter 2026 financial results, including Q2 2026 cash position (€318 million), R\u0026D expenses (€35.0 million), G\u0026A expenses (€15.8 million), and net loss (€47.8 million or €0.70 per share). The document explicitly states \"announced financial results for the second quarter ending on June 30, 2026\" and includes a \"Second Quarter 2026 Financial Results\" section with key financial metrics. While the release also contains business updates on clinical trials and a corporate promotion, the primary disclosure is the quarterly financial results, which is material to investors assessing the company's financial position and burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:52:46.142124+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28334,"accession_number":"0001193125-26-345702","item_number":"EX-99.1","item_title":"phvs-ex99_1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing Pharvaris' second quarter 2026 financial results, including Q2 2026 cash position (€318 million), R\u0026D expenses (€35.0 million), G\u0026A expenses (€15.8 million), and net loss (€47.8 million or €0.70 per share). The document explicitly states \"announced financial results for the second quarter ending on June 30, 2026\" and includes a \"Second Quarter 2026 Financial Results\" section with key financial metrics. While the release also contains business updates on clinical trials and a corporate promotion, the primary disclosure is the quarterly financial results, which is material to investors assessing the company's financial position and burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:52:46.142124+00:00","company_name":"Pharvaris N.V.","ticker":"PHVS","filing_date":"2026-08-12"},{"id":28335,"accession_number":"0001193125-26-345702","item_number":"EX-99.2","item_title":"phvs-ex99_2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Management's Discussion and Analysis (MD\u0026A) accompanying unaudited condensed consolidated interim financial statements for the six months ended June 30, 2026. The document explicitly references \"our unaudited condensed consolidated interim financial statements, including the notes thereto, for the three and six months ended June 30, 2026 and 2025 included as Exhibit 99.3.\" This is a periodic interim financial report, not a discrete event or earnings release press announcement. As a foreign private issuer's interim financial disclosure, it should be classified as `periodic_interim` and deferred for separate processing rather than treated as a material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:52:46.142124+00:00","company_name":"Pharvaris N.V.","ticker":"PHVS","filing_date":"2026-08-12"},{"id":28336,"accession_number":"0001193125-26-345702","item_number":"EX-99.3","item_title":"phvs-ex99_3.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.98,"reasoning":"This exhibit is an unaudited condensed consolidated interim financial report for the six months ended June 30, 2026, comprising a statement of loss and comprehensive loss, statement of financial position, statement of changes in equity, statement of cash flows, and supporting notes. It is a periodic financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings press release. The document is explicitly labeled \"Unaudited Condensed Consolidated Interim Financial Statements\" and covers an interim period, not a full year.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:52:46.142124+00:00","company_name":"Pharvaris N.V.","ticker":"PHVS","filing_date":"2026-08-12"}]}